{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:53:43Z","timestamp":1780617223141,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cervical cancer is caused by Human Papilloma viruses (HPV) and is preceded by precursor stages: Cervical Intraepithelial Neoplasia (CIN). CIN is mostly found in women in their reproductive age and treated with a Loop Electrosurgical Excision Procedure (LEEP). The recurrence or residual disease rate after treatment is up to 17%. These women have a lifelong increased risk of recurrent CIN, cervical cancer and other HPV related malignancies. Furthermore, LEEP treatments are associated with complications such as premature birth. Limited data show that prophylactic HPV vaccination at the time of LEEP reduces recurrence rates, therefore leading to a reduction in repeated surgical interventions and side effect like preterm birth.<\/jats:p>\n<jats:p>The primary study objective is to evaluate the efficacy of the nonavalent HPV vaccination in women with a CIN II-III (high-grade squamous intraepithelial lesion (HSIL) lesion who will undergo a LEEP in preventing recurrent CIN II-III after 24\u2009months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This study is a randomised, double blinded, placebo controlled trial in 750 patients without prior HPV vaccination or prior treatment for CIN and with histologically proven CIN II-III (independent of their hrHPV status) for whom a LEEP is planned. Included patients will be randomised to receive either three injections with nonavalent (9 HPV types) HPV vaccine or placebo injections (NaCL 0.9%) as a comparator. Treatment and follow-up will be according the current Dutch guidelines. Primary outcome is recurrence of a CIN II or CIN III lesion at 24\u2009months. A normal PAP smear with negative hrHPV test serves as surrogate for absence of CIN. At the start and throughout the study HPV typing, quality of life and cost effectiveness will be tested.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>Although prophylactic HPV vaccines are highly effective, little is known about the effectivity of HPV vaccines on women with CIN. Multiple LEEP treatments are associated with complications. We would like to evaluate the efficacy of HPV vaccination in addition to LEEP treatment to prevent residual or recurrent cervical dysplasia and decrease risks of repeated surgical treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Medical Ethical Committee approval number: NL66775.078.18. Affiliation: Erasmus Medical Centre. Dutch trial register: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/7938\">NL 7938<\/jats:ext-link>. Date of registration 2019-08-05.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07025-7","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T13:20:04Z","timestamp":1591708804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"R. L. O.","family":"van de Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hofhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. G.","family":"Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J. G.","family":"Melchers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"van Kemenade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L. M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"12","key":"7025_CR1","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","volume":"22","author":"M Arbyn","year":"2011","unstructured":"Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675\u201386.","journal-title":"Ann Oncol"},{"issue":"9590","key":"7025_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890\u2013907.","journal-title":"Lancet."},{"issue":"7","key":"7025_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"GY Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"7025_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<55::AID-IJC11>3.0.CO;2-U","volume":"83","author":"P Nieminen","year":"1999","unstructured":"Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous pap-smear screening for cervical cancer: a case-control study. Int J Cancer. 1999;83(1):55\u20138.","journal-title":"Int J Cancer"},{"issue":"5","key":"7025_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1470-2045(11)70078-X","volume":"12","author":"M Kocken","year":"2011","unstructured":"Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12(5):441\u201350.","journal-title":"Lancet Oncol"},{"key":"7025_CR6","doi-asserted-by":"crossref","unstructured":"van der Heijden E, Lopes AD, Bryant A, Bekkers R, Galaal K. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 2015;1.","DOI":"10.1002\/14651858.CD010757.pub2"},{"key":"7025_CR7","doi-asserted-by":"publisher","first-page":"i3633","DOI":"10.1136\/bmj.i3633","volume":"354","author":"M Kyrgiou","year":"2016","unstructured":"Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.","journal-title":"BMJ."},{"issue":"1","key":"7025_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00404-013-2955-0","volume":"289","author":"G Jin","year":"2014","unstructured":"Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet. 2014;289(1):85\u201399.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"7025_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/AOG.0000000000001777","volume":"128","author":"T Bjorge","year":"2016","unstructured":"Bjorge T, Skare GB, Bjorge L, Trope A, Lonnberg S. Adverse pregnancy outcomes after treatment for cervical intraepithelial Neoplasia. Obstet Gynecol. 2016;128(6):1265\u201373.","journal-title":"Obstet Gynecol"},{"issue":"7629","key":"7025_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bmj.39363.471806.BE","volume":"335","author":"B Strander","year":"2007","unstructured":"Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335(7629):1077.","journal-title":"BMJ."},{"issue":"22","key":"7025_CR11","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2016.71.4543","volume":"35","author":"RMF Ebisch","year":"2017","unstructured":"Ebisch RMF, Rutten DWE, IntHout J, Melchers WJG, Massuger L, Bulten J, et al. Long-lasting increased risk of human papillomavirus-related carcinomas and Premalignancies after cervical intraepithelial Neoplasia grade 3: a population-based cohort study. J Clin Oncol. 2017;35(22):2542\u201350.","journal-title":"J Clin Oncol"},{"key":"7025_CR12","doi-asserted-by":"crossref","unstructured":"Loopik DL, Ebisch RM, IntHout J, Melchers WJ, Massuger LF, Bekkers RL, et al. The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: a population-based study. Int J Cancer. 2019.","DOI":"10.1002\/ijc.32834"},{"issue":"2","key":"7025_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","volume":"18","author":"M Lehtinen","year":"2019","unstructured":"Lehtinen M, Baussano I, Paavonen J, Vanska S, Dillner J. Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev Vaccines. 2019;18(2):153\u201360.","journal-title":"Expert Rev Vaccines."},{"key":"7025_CR14","doi-asserted-by":"crossref","unstructured":"Arbyn M, Bryant A, Beutels P, Martin-Hirsch PP, Paraskevaidis E, Van Hoof E, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2011;2011(4).","DOI":"10.1002\/14651858.CD009069"},{"issue":"12","key":"7025_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","volume":"17","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018;17(12):1085\u201391.","journal-title":"Expert Rev Vaccines"},{"issue":"19","key":"7025_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Group FIS","year":"2007","unstructured":"Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"7025_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","volume":"130","author":"WD Kang","year":"2013","unstructured":"Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130(2):264\u20138.","journal-title":"Gynecol Oncol"},{"key":"7025_CR18","doi-asserted-by":"crossref","unstructured":"Oura Elmar A, Garland Suzanne M, Paavonen Jorma, Ferris Daron G, Perez Gonzalo, Ault Kevin A et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401.","DOI":"10.1136\/bmj.e1401"},{"issue":"1","key":"7025_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaad.2019.04.067","volume":"82","author":"CT Pham","year":"2020","unstructured":"Pham CT, Juhasz M, Sung CT, Mesinkovska NA. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: a literature review. J Am Acad Dermatol. 2020;82(1):202\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"7025_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/infdis\/jiy616","volume":"219","author":"T Rosenberg","year":"2019","unstructured":"Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig AK, Wehberg S, Chirila M, et al. Therapeutic use of the human papillomavirus vaccine on recurrent respiratory Papillomatosis: a systematic review and meta-analysis. J Infect Dis. 2019;219(7):1016\u201325.","journal-title":"J Infect Dis"},{"issue":"6","key":"7025_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaoto.2016.4736","volume":"143","author":"GR Dion","year":"2017","unstructured":"Dion GR, Teng S, Boyd LR, Northam A, Mason-Apps C, Vieira D, et al. Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review. JAMA Otolaryngol Head Neck Surg. 2017;143(6):614\u201322.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"7025_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","volume":"151","author":"A Ghelardi","year":"2018","unstructured":"Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018;151(2):229\u201334.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"7025_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","volume":"9","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9(6):347\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"7025_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/13697137.2019.1600500","volume":"22","author":"LS Velentzis","year":"2019","unstructured":"Velentzis LS, Brotherton JML, Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric. 2019;22(6):596\u2013602.","journal-title":"Climacteric."},{"key":"7025_CR25","unstructured":"Guideline CIS, AIS and VAIN 2015-11-12, Version: 1.0. https:\/\/www.oncoline.nl\/cin-ais-en-vain.."},{"issue":"10197","key":"7025_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509.","journal-title":"Lancet."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07025-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:20:18Z","timestamp":1623194418000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07025-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7025"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07025-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study will be carried out according to the standards outlined in the Declaration of Helsinki. The medical ethical committee of the Erasmus Medical Centre has approved the study protocol (version 2.0; 21 March 2019, NL 66775.078.18). Prior to registration written informed consent will be obtained in all patients. Randomization happens after signing of the Informed Consent. All data will be anonymously processed. Participants will be able to resign at any time without statement of reasons.Patients from the following Dutch hospitals may be included: Amphia (Breda), Bernhoven (Uden) Catharina hospital (Eindhoven), Deventer Hospital (Deventer), Diakonessenhuis (Utrecht), Dijklander Hospital (Hoorn), Erasmus MC (Rotterdam), Flevo Hospital (Almere), Franciscus Gasthuis (Rotterdam), Gelre Hospital (Apeldoorn), Gelre Hospital (Zutphen), IJsselland Hospital (Rotterdam), Isala klinieken (Zwolle), Jeroen Bosch (Den Bosch), LUMC (Leiden), Reinier de Graaf Groep (Delft), VieCurie MC (Venlo), Zuyderland MC (Heerlen).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F.J. Van Kemenade is an Editorial Board member for the journal. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"539"}}